1. Toluene (TOL) is widely used in industry. Occupational exposure to TOL is commonly assessed using TOL in blood, hippuric acid and ortho-cresol. Levels of these biomarkers may depend on factors potentially interfering with TOL biotransformation, such as the presence of other solvents in the workplace. Mercapturic acids (MAs) could be an alternative to the "traditional" TOL biomarkers.
Introduction
In an occupational environment, individuals are often exposed to mixtures of chemicals, rather than to a single compound. Depending on the mixtures' composition, toxicological interactions between components may occur. These interactions are complex and difficult to predict, and they may induce greater than additive, additive or subadditive effects (Cassee et al., 1998) .
In general, occupational exposure limits (OEL), or biological limit values (BLV) are almost always established based on single exposures to pure substances. These values might therefore not be appropriate when monitoring exposure to mixtures including a particular chemical (Viau, 2002) . For atmospheric monitoring, the concept of additivity is often applied; thus, the effects of a mixture are estimated by considering the sum of its components (ATSDR, 2004) . However, no current recommendations suggest adjusting biological indicators of exposure in these situations.
A number of additive mixtures are commonly used and have been identified in the workplace (Pohl et al., 2009) , and web-based software can be used to determine potential additivity or interaction between compounds in these mixtures (Vyskocil et al., 2007) . The study of certain mixtures composed of chemicals of the same family was prioritized (Pohl et al., 2003) . For some of these mixtures, e.g. BTEX (benzene, toluene, ethylbenzene and xylenes), models have been proposed (Haddad et al., 1999) . Despite attempts to simplify these models for use by occupational health professionals, they are still very complex and remain mainly used by specialists (Bois, 2010; Mumtaz et al., 2012) . Moreover, the input parameters for these models are not always readily available.
Finally, despite the sophistication of these models, they do not really explain the results observed in analysis of urine samples.
In this study, we focus on blood and urinary biomarkers of toluene (TOL) exposure in multiple exposure contexts. TOL is a widely used industrial solvent (Triolet, 2005; Nagasawa et al., 2011; Estevan et al., 2012) , with an annual consumption close to 20 million tons. It is mainly used as a component in paints, varnishes, printing inks, adhesives, waxes, etc. It is also used as feedstock for the manufacture of multiple products (ATSDR, 2000) . It is classified by the European Chemical Agency as reprotoxic category 2 (suspected of damaging fertility or inducing risk of harm to the unborn child) and may cause damage to the central nervous system upon inhalation (ECB, 2003) .
TOL is also considered ototoxic and can exacerbate the effect of noise on hearing (Campo et al., 2013) .
To assess occupational exposure to TOL, hippuric acid (HA) and ortho-cresol (oCre) in urine, or TOL in blood (Tol-B) , are usually measured. HA is derived from the major TOL metabolic pathway (83-94% of urinary metabolites) (Figure 1 ). However, because it is also endogenously produced, it lacks sensitivity for exposure levels below the threshold limit value (50 ppm in France) (Angerer and Kramer, 1997; Ikeda et al., 2008) . Its low specificity and individual variations in metabolism make it unreliable for individual monitoring. Urinary oCre is excreted a sulfate or glucuronide ( Figure 1 ).
With its two isomers: meta-and para-cresols (mCre and pCre), it accounts for less than 5% of TOL metabolites. As it is more specific than HA, and presents good sensitivity around 50 ppm, it can be used to confirm exposure in case of doubt (Truchon et al., 1999) . However, its use is limited at lower concentrations (under 2 ppm) . For all atmospheric TOL levels (Tol-A), Tol-B measured in samples taken at the end of a shift is the most specific indicator of TOL exposure . Due to the "invasive" nature of blood sampling, analysis of urinary TOL is preferred (Fustinoni et al., 2000; Kawai et al., 2008) . This can be problematic as particular care must be taken when measuring urinary TOL to avoid sample contamination or possible losses due to evaporation (Ducos et al., 2008) .
Other indicators of TOL exposure can also be considered. Among them, mercapturic acids (MAs), are minor metabolites which result from the glutathione pathway. These biomarkers have not been extensively studied (Haufroid and Lison, 2005) (Figure 1 ). Only benzylmercapturic acid (BMA) has been compared with other indicators (Inoue et al., 2004; Ikeda et al., 2008) . In contrast, para-toluylmercapturic acid (pTMA) has not been exhaustively evaluated (Angerer et al., 1998) , nor have the two last representatives of this metabolite family: ortho-and meta-toluylmercapturic acids (oTMA and mTMA), which were recently detected in rat urine following TOL exposure (Cosnier et al., 2012) . In rats exposed to TOL vapors (between 2 and 500 ppm) the four MAs were compared to Tol-B, HA and oCre. We demonstrated that the concentrations of the four MAs correlate as well as Tol-B with Tol-A, and that MAs are clearly more suitable than oCre and HA as excreted TOL biomarkers (Cosnier et al., 2013) .
The purposes of this study, also performed in rats, were firstly, to investigate the effects of mixed vapors on the TOL metabolism and secondly, to appraise the relevance of MAs as biomarkers of TOL exposure in such a context. For this, we measured after co-exposures the different biomarkers (Tol-B, HA, oCre, BMA, oTMA, mTMA and pTMA) and assessed how MAs behave compared to the traditional TOL biomarkers (Tol-B, HA and oCre). Four binary mixtures, considered as plausible industrial cases, were tested: TOL with ethyl acetate (EtAc), TOL with n-butanol (BuOH), TOL with methylethylketone (MEK), and TOL with xylenes (XYLs). For each mixture, we studied two general scenarios to determine the relationships between each indicator and Tol-A, as follows: (1) increasing the co-solvent concentration while Tol-A was maintained at the OEL, and (2) increasing the Tol-A concentration while maintaining co-solvent concentrations close to their OEL.
Materials and methods

Animals
Male Sprague-Dawley rats were purchased from Charles Rivers Laboratories (Saint Germain sur l'Arbresle, France) and weighed between 200 and 220 g on arrival at the animal facility. Before exposure, all animals were acclimatized for at least 2 weeks with a 12:12 h day/night cycle in polycarbonate cages containing irradiated corn cob LabCob12 bedding (DIETEX, Saint Gratien, France) and covered with spun-bonded polyester cage filter. A04 irradiated feed (SAFE, Augy, France) and tap water were available ad libitum. The temperature in the animal quarters was 22 ± 2 °C and the relative humidity was 55 ± 10%. Animal experiments were performed according to ethical regulations of animal experimentation (European Directive 2010/63/EU) in a French Ministry of Agriculture-accredited animal facility (Accreditation N° C 54-547-10).
Mixture compositions and inhalation exposure
Twenty six inhalation experiments were performed. The first groups of rats were exposed to TOL at 2, 5, 20, 50, 200 and 500 ppm, which correspond to 0.1, 1 and 10 times the American and French 8-hour OELs: 20 and 50 ppm (until July 2012), respectively. The results from these groups were partially reported in a previous study (Cosnier et al., 2013) .
The second groups of animals were exposed to four binary mixtures: TOL/EtAc, TOL/BuOH, TOL/MEK and TOL/XYLs (isomolar mixture of the three xylene isomers). These binary mixtures were selected based on data obtained from French industrial sectors where TOL is used (Triolet, 2005) . Co-solvents were selected from the most frequently and abundantly used compounds in the different industries. Only one compound from each chemical family was tested. EtAc, BuOH, MEK and XYLs were considered to be representative of esters, alcohols, ketones and aromatic solvents, respectively. Five different compositions per mixture were investigated, as detailed in Table 1 .
Groups of eight rats (one concentration per group) were exposed to TOL vapors or mixtures in 200 L glass/stainless steel inhalation chambers. Animals were exposed for 6 hours/day (from 09:00 am to 03:00 pm), 5 days/week for one week. Exposure parameters (temperature, humidity, air flow, pollutant concentrations, etc.) were followed in accordance with OECD guideline 403 for chemical testing (acute inhalation toxicity). During the 6-h exposure, rats did not have access to food or water.
In the inhalation chambers, the animals were separated from each other by small-mesh wire fences.
The inhalation chambers were designed to sustain a dynamic and adjustable airflow (5-6 m 3 /h); they were maintained at a negative pressure of no more than 5 mm H2O to prevent any leakage of the test compound. Air entering the chamber was filtered and conditioned at a temperature of 22 ± 1 °C and a humidity of 55 ± 10%. Vapors were generated using a thermoregulated glass streamer. The solvents, delivered by pumps or syringes, were instantaneously vaporized upon contact with the heated surface and carried forward with an additional airflow through the streamer, into the main air inlet pipe of the exposure chambers. Unexposed rats (controls) were maintained in similar chambers, but exposed to clean air only.
Exposure levels were measured three times during the 6-h exposure (at 10:00 am, 12:00 pm and 2:00 pm) by collecting samples from the chamber's atmosphere using glass tubes packed with activated charcoal 18-35 mesh (VWR International S.A.S, Fontenay-sous-Bois, France). Solvents were desorbed from the activated charcoal using carbon disulfide. Internal standards were added to samples before analysis (styrene for TOL, propyl acetate for EtAc, BuOH and MEK, or mesitylene for XYLs).
Samples were analysed with a Varian CP-3800 gas chromatograph (GC) (Bruker Daltonics, Wissembourg, France) equipped with a flame ionization detector. They were assayed on a 30 m x 0.53 mm (1.5 µm film thickness) CP-Sil 5 column (Varian), using helium as the carrier gas at a constant flow of 10 mL/min. The column temperature program was: 40 °C for 2 min then increased to 190 °C at a rate of 15 °C/min. The temperature was held at 190 °C for 1 min. The injector (Flash 1061) and detector were maintained at 240 °C and 250 °C, respectively. These analyses were used to perform daily calibrations.
During exposure, a second GC (Clarus 500, Perkin Elmer, Courtaboeuf, France), equipped with a flame ionization detector and an automatic gas sampling valve, was used to perform online concentration measurements every minute to check the stability of vapor generation throughout exposure.
Blood sample collection
Blood TOL concentrations were measured after the first and fifth days of exposure. While atmospheric concentrations are held constant in inhalation chambers, rats were removed one by one using an airlock. Blood collection had to be performed and completed on one rat before taking out another animal from the chamber. The procedure for this was detailed in Cosnier et al. (2013) .
Briefly, blood was collected from the tails of rats anaesthetized with isoflurane; sampling was completed within 5 min. In these experimental conditions and considering that the average elimination half-lives of TOL in blood was approximately 6 -7 min, blood TOL concentration was approximately 40% lower than what could be expected from the actual exposures. Blood samples (~ 0.8 mL) were dispensed into 2-mL heparinized vials and frozen at -20 °C. Blood samples were then extracted with carbon disulfide (CS 2 ) containing p-xylene as an internal standard. After shaking and centrifugation, the CS 2 layer, containing the TOL, was analysed using the chromatographic conditions described for atmospheric monitoring. In these conditions, the TOL limit of detection (LOD) was 0.072 µmol/L of blood and the reproducibility was ≤ 5 %.
Urine collection
After blood collection, animals were placed in individual metabolic-type stainless steel cages with free access to food and water from 3:00 pm to 9:00 am the following day. During this 18-h period, urine was collected and refrigerated by a cooling system surrounding the collection tubes. Urine samples were frozen immediately after collection and stored at -20 °C. They were thawed just before analysis.
The different urinary metabolites: HA, oCre, oTMA, mTMA, pTMA, and BMA were measured, as previously detailed in (Cosnier et al., 2012; Cosnier et al., 2013) . For these assays, LODs in urine (in µmol/L) were 22.3 for HA, 0.3 for oCre, 0.01 for oTMA and mTMA, and 0.02 for pTMA and BMA.
Reproducibilities over the entire concentration ranges investigated were ≤2% for HA, <13% for oCre, <9% for oTMA, <7% for mTMA, ≤8% for pTMA and ≤12% for BMA.
Statistical analysis
All statistical analyses were performed using Stata 12.1 (Stata College station, Texas, USA).
Normality and homogeneity of variances were tested for all data. The means and standard errors are reported in Tables 2 and 3 for all indicators. To normalise the data and homogenise variances, the data were then log-transformed before performing statistical tests.
Different protocols were used to analyse how the different indicators responded to variations in: (1) co-solvent concentration (constant Tol-A), or (2) Tol-A concentration (constant co-solvent concentration).
In the first case (Tol-A = 50 ppm), the results were analyzed in two steps, as follows:
-The relationship between the log of the concentrations of the different indicators and the concentration of co-solvent (after ln + 1 transformation) were subjected to independent linear mixed-effect modeling. These models test 1) the concentration-response relationship, 2) the day effect (after Bonferroni correction), and 3) the concentration/day interaction.
-ANOVA was run to test the effect of co-solvent concentrations for each indicator. When this effect was significant, a post-hoc test for multiple comparisons (Dunnett) was used to compare the mixture-exposed groups to the control group (exposed to TOL alone).
In experiments in which the co-solvent concentration was equal to its 8-h OEL, another linear mixedeffect model was used to test the following: 1) the concentration-response during exposure to TOL alone, 2) the concentration-response with co-exposure, 3) the differences between the slopes of regression lines (mixtures vs. TOL alone) (∆ slope ), 4) the difference between the values obtained for
Tol-A = 50 ppm, with or without co-exposure (∆ concentration ), and 5) the day effect (not detailed in this paper). The data provided by this model allowed toxicological interactions to assessed. Several scenarios were possible: a) If ∆ slope and ∆ concentration were both zero; then there was no interaction.
b) If ∆ concentration equal zero but ∆ slope was different from zero; then it indicated an interaction in accordance with Gennings et al. (2005) who proposed the "changes in slope" analysis as a unifying concept to assess toxicological interactions. According to the authors, if the slope of the dose-response curve for one compound is constant in the presence of other chemicals there is no interaction, whereas if the slope is affected it indicates an interaction. c) If ∆ concentration was different from zero but ∆ slope equal zero and, d) if ∆ concentration and ∆ slope were different from zero; then there was also an effect of the co-exposure.
Results
Effect of increasing co-solvent concentration with Tol-A maintained at 50 ppm
The concentration of each indicator was measured at the end of the first and fifth days of exposure, Table 2 shows the means and standard deviations expressed in µmol/L (or mmol/L for HA) to make direct comparisons between biomarkers and experiments easier.
The effects of co-exposure on Tol-B depended on the nature of the co-solvent (Figure 2A ). For TOL/BuOH and TOL/EtAc co-exposures, Tol-B significantly decreased, whereas TOL/XYLs and TOL/MEK mixtures provoked an increase related to the co-solvent concentration (Table 3 ). More specifically, TOL50/XYLs400 and TOL50/MEK1400 induce a 4-to 5-fold increase in Tol-B (18.4
and 22.1 µmol/L, respectively) as compared to exposure to TOL50 alone (5.3 µmol/L) on day 1. For the TOL/MEK mixture, it is of note that the Tol-B concentration depends on the day of the measurement: concentrations obtained on day 5 were systematically lower than those obtained on day 1, regardless of the atmospheric MEK concentration (MEK-A) ( Table 2) . This difference was observed even with low MEK-A concentrations.
For the urinary biomarkers, co-exposure had marginal effects on HA concentration (Table 2) .
For oCre ( Figure 2B ), no clear effect was seen with TOL/EtAc. In contrast, a significant reduction in oCre was observed with TOL/BuOH and TOL/XYLs at the highest co-solvent concentrations, 100
and 400 ppm, respectively (Table 2) . For TOL/MEK exposure, at all MEK-A concentrations, urinary oCre concentrations were 2-3 times higher (30.0 µmol/L for TOL50/MEK200 on day 1) than with TOL50 exposure alone (11.4 µmol/L).
MAs were split into two groups defined by the location of the oxidation during the first step of TOL metabolism. BMA is produced by side-chain oxidation, whereas TMAs are derived from ring oxidation (ΣTMAs = oTMA + mTMA + pTMA) (Figure 1 ). Finally, ΣMAs correspond to BMA plus ΣTMAs. Figure 2C displays the urinary ΣMAs measured after exposure to the various mixtures.
While TOL/EtAc and TOL/XYLs did not have a significant effect on ΣMAs excretion, TOL/BuOH mixtures did significantly affect MAs production ( Figure 2C ). In detail, the statistical analysis revealed that BMA was reduced with 100 ppm BuOH ( Figure 2C ).
Effect of increasing Tol-A while maintaining an atmospheric concentration of co-solvent equal to 8h
OEL
The effect on Tol-B, HA, oCre and ΣMAs of increasing Tol-A levels during mixture exposure when co-solvent concentrations were maintained at their OEL is shown in Figure 3 . The data obtained for these biomarkers when Tol-A was equal to either 5 or 500 ppm are summarized in Table 3 . The doseresponse relationships for each indicator in single and co-exposure conditions were analysed; the results and the significance of ∆ slope (mixtures vs. TOL alone) and ∆ concentration (at 50 ppm Tol-A) are presented in Table 4 .
EtAc did not significantly affect Tol-B, whatever the level of Tol-A ( Figure 3A ). Table 4 indicates no statistical difference at 50 ppm Tol-A for HA, oCre and ΣMAs. However, the significant slope differences between TOL and TOL/EtAc exposures show that oCre ( Figure 3E ) and ΣMAs ( Figure   3G ) concentrations were slightly lower with co-exposure at 5 ppm Tol-A, whereas they were slightly higher at 500 ppm Tol-A. Despite appearances, the same cannot be said for HA, since the mean level in control animals (not exposed) was 3.4 mmol/L (0.61 g/L) (shaded area in Figure 3C ). Below this value, no conclusion can be drawn.
Dose-response curves also cross for urinary biomarkers measured following TOL/BuOH exposure ( Figure 3D , 3F, and 3H), but there is no statistical difference at 50 ppm Tol-A (Table 4 ). In contrast, the HA concentration obtained with TOL500/BuOH20 was twice that obtained with TOL500 alone ( Figure 3D ). Tol-B levels (measured in blood) show that co-exposure with BuOH induced a slight but significant reduction when Tol-A ≤ 50 ppm ( Figure 3B ) (positive ∆ slope and negative ∆ concentration in Table 4 ).
Co-exposure with MEK-A at 200 ppm induced a systematic increase in Tol-B ( Figure 3A ) and in its metabolites ( Figure 3C , 3E and 3G) (positive ∆ concentration in Table 4 ). This increase was more significant with lower Tol-A levels (negative ∆ slope for Tol-B and ΣMAs). For MAs, the increase was greater for BMA than ΣTMAs (Tables 2 and 3 ) (∆ slope and ∆ concentration not significant for ΣTMAs).
Finally, TOL/XYLs showed a similar profile to TOL/MEK mixtures, with a consistently higher Tol-B concentration after co-exposure ( Figure 3B and positive ∆ concentration in Table 4 ). Urinary indicators were not as consistent in this scenario; for example, HA production was boosted by the presence of 50 ppm XYLs ( Figure 3D and Table 4 ), while MAs excretion was unaffected ( Figure 3H and Table 4 ).
The effect of 50 ppm XYLs on oCre ( Figure 3F ), depended on Tol-A: thus, the amount excreted after co-exposure was lower at 5 and 50 ppm Tol-A (negative ∆ concentration ) and higher at 500 ppm Tol-A than that excreted after exposure to TOL alone (positive ∆ slope ).
How biomarker levels relate to airborne toluene levels
As previously mentioned, the relationships between the different indicators and Tol-A with or without co-solvent were independently modeled using linear mixed-effect models. Table 5 
Discussion
TOL metabolism is similar in humans and rats, thus making animal models suitable for its study.
Indeed, results obtained in rats with HA, oCre and Tol-B can be transposed to humans rather directly because the percentage of these biomarkers excreted in urine or dissolved in blood respect to the inhaled dose are comparable (ATSDR, 2000; ECB, 2003; Cosnier et al., 2013) . It is however noted that MAs formation is ten to hundred times greater in rats than in humans (Angerer et al., 1998; Inoue et al., 2004; Ikeda et al., 2008; Inoue et al., 2008; Cosnier et al., 2013) . From an analytical point of view, this species difference would not be a problem since rather simple analytical methods are now available to measure low levels of these MAs (Cosnier et al., 2012) .
In this investigation, all of the tested conditions can be considered as plausible industrial cases. The co-solvents studied (EtAc, BuOH, MEK and XYLs) were chosen because they are frequently used in combination with TOL (Triolet, 2005; Nagasawa et al., 2011; Estevan et al., 2012) . To make the compositions of the mixtures realistic, the highest concentrations of the co-solvents used were those found in the Solvex database (INRS) which lists field measurements.
The results clearly show that co-exposure does not systematically impact TOL metabolism. Indeed, whether interaction occurs depends on both the nature and the concentrations of the substances making up the mixture. For instance, we found that EtAc has little influence on TOL metabolism.
This contrasts with a report by Freundt et al. (1989) who indicated a decrease in Tol-B (or in ethylbenzene, m-xylene or mesitylene blood concentration) upon co-exposure with EtAc. This apparent discrepancy could be due to the different concentrations used in this study compared to those used by Freundt et al. (1989) (140, 230, 420 and 690 ppm for TOL and 1000 and 4000 ppm for EtAc).
If we detail the metabolisms of TOL and EtAc, it appears that aldehyde and alcohol dehydrogenases (ALDH and ADH) are involved in both metabolisms. For EtAc, ALDH and ADH transform acetic acid and ethanol (produced by carboxylesterase enzymes) in acetaldehyde (INRS, 2011), whereas for TOL, they act successively to transform benzyl alcohol in benzoic acid: the precursor of HA (ATSDR, 2000) . Thus, if a metabolic competition occurs, it is not during the first step of oxidation of TOL; this may therefore explain the weak interaction at low concentrations.
To our knowledge, this investigation is the first studying TOL/BuOH interaction, although coexposure data obtained with this mixture could be compared to that obtained with other mixtures, such as TOL/isopropanol, TOL/methanol or XYLs/BuOH (Kawai et al., 1992; Swiercz et al., 1995; Uaki et al., 1995; Hori et al., 1999; Ishidao et al., 2000) . Our findings, and those previously published, demonstrate that a metabolic interaction exists between TOL (or XYLs) and a high concentration of alcohol upon inhalation by rats, workers or volunteers. Alcohols appear to increase the rate of TOL metabolism, which reduces the biological half-life of TOL in blood. This may be explained by the induction of cytochrome P450 isoenzyme (CYP2E1) which is involved in the transformation of TOL to benzyl alcohol (ATSDR, 2000; Pohl and Scinicariello, 2011) .
Consequently, the Tol-B measured just after co-exposure with an alcohol is lower than that measured at the end of exposure to TOL alone. Concomitantly, urinary metabolites rise rapidly during the exposure period, and drop off afterward. In our study, all measurements were carried out after inhalation, so that a reduction in Tol-B and urinary metabolites concentrations (oCre and MAs) was observed, even at low BuOH concentrations (2 ppm). In contrast, co-exposure to TOL500/BuOH20 increases the production of HA and oCre. A 2 ppm level of BuOH may seem low to induce the activity of CYP2E1 (after only 6 hours of exposure). Hori et al. (1999) (for TOL/methanol coexposure) hypothesise that the decrease in Tol-B after co-exposure would be due to a difference in the vapor uptake rate or partition coefficient which may result in more BuOH and less TOL distributed in blood.
As previously reported in rats and humans, TOL/XYLs mixtures (aromatic compounds) may mutually inhibit metabolism at high levels of exposure (Wallen et al., 1985; Tardif et al., 1991; Tardif et al., 1992; Tardif et al., 1993) . In that case, the mechanism of interaction is a competitive inhibition of hepatic metabolism; TOL and XYLs are known substrates for CYP2E1 (Haddad et al., 1999) .When
Tol-A or atmospheric XYLs (XYLs-A) are below or equal to OELs, the blood solvent burden and excretion of HA or oCre is only slightly influenced by the type of exposure (single or multiple), while for XYLs-A levels above the OEL, HA excretion is significantly delayed (Mao et al., 2007) . In this study, a significant increase in TOL blood burden (up to 3-fold) was measured after co-exposure with as little as 50 ppm XYLs-A. oCre excretion was only weakly impacted by the presence of XYLs; a delay in the production and excretion of this metabolite has only been observed with unbalanced mixtures (i.e. TOL5/XYLs50 and TOL50/XYLs400). However, an unexpected increase in HA and oCre concentrations was measured with TOL500/XYLs50. As far as we know, no previous study has investigated MAs in this exposure context. Our data did not show any effect of TOL/XYLs coexposure on MAs excretion.
Our data show TOL/MEK mixtures to behave differently to the other mixtures tested. No previous report of an interaction between these two solvents has been published. Indeed, human toxicokinetics studies at low exposure levels reported no interaction, whereas in rats interaction may occur at high intensities (Ukai et al., 1994; Uaki et al., 1995) . Our results clearly show a TOL-MEK interaction.
After co-exposure, Tol-B increased markedly for all the TOL/MEK mixtures studied. With the TOL50/MEK200 mixture, the TOL blood burden was increased 4-fold. A similar effect was observed with male rats exposed to vapors of TOL (or XYLs) and acetone (Vodickova et al., 1995) and in two studies on XYLs/MEK mixtures (Liira et al., 1988; Liira et al., 1991) . In each case, clearance of TOL, and even more so of XYLs, was slowed by co-exposure to acetone or MEK. This could indicate that TOL or XYLs metabolism is inhibited in the presence of these ketones. For the urinary biomarkers, the trend is for an increase in metabolite concentrations (from 20 ppm MEK). It may seem odd that co-exposure with MEK increases every biomarkers, both unmetabolized Tol-B and urinary metabolites. After verification, we have excluded the possibility that MEK interferes with assays of Tol-B or with those of urinary metabolites. We controlled also that MEK did not significantly affect breath in such a way that the TOL uptake would be increased. Moreover, the total concentration of metabolites remains consistent with the estimated amount of TOL absorbed during a 6-h TOL50 exposure which is approximately 70 µmol considering a respiratory volume of 190 cm 3 /min (Schulz and Muhle, 2000) and a TOL absorption rate of 50 % (ATSDR, 2000). Indeed, considering an average urinary volume of 11.4 mL, the total concentration of metabolites excreted by a rat during the 18-h post-exposure should not exceed 6.15 mmol/L, which is always the case (except for TOL50/MEK on day 1). Furthermore, after a sharp increase, the oCre and MAs concentrations also decreased relative to the increase in the intensity of co-exposure between MEK200 and MEK1400, when Tol-A is maintained at 50 ppm. Few studies dealt with the metabolism of the MEK in rat. However, it would seem that the majority of MEK is oxidized to 3-hydroxy-2-butanone by the cytochrome P450 monooxygenase system (P450IIE1 and IIB isozymes) (Raunio et al., 1990; EPA, 2003; Pohl and Scinicariello, 2011) . The only observation of blood results would indicate a competitive inhibition between MEK and TOL even though urinary measurements are not completely consistent with this assumption. Since 1400 ppm MEK-A is required to observe urinary concentrations lower than those measured with TOL50 exposure alone, it seems that the kinetics of metabolite excretion are less delayed than with TOL/XYLs mixtures. Another explanation for this unexpected behavior may be the role played by 2-butanol, which is in equilibrium with MEK during its metabolism (EPA, 2003) .
Perhaps the 2-butanol, like the BuOH (1-butanol), induces TOL metabolism, therefore counteracting the effect of MEK. Further work is needed to fully explore this interaction.
Conclusion
From a prevention point of view, TOL/XYLs and TOL/MEK mixtures may both potentiate the effects of TOL. If we consider that the toxic effects of TOL are due to the mother molecule (unchanged) and not to its metabolites, an increase in blood concentration could have a negative impact on employees' health.
A TOL5/MEK200 mix represents a typical case of possible risk underestimation. Following co-exposure to this mixture, Tol-B is equal to 1.72 µmol/L (0.17 mg/g), which is close to that obtained with exposure to 15 to 20 ppm TOL alone (Cosnier et al., 2013) . This is the current limit value recommended by American Conference of Governmental Industrial Hygienists and France (since July 2012). In such case, OELs may be too high to protect employees from the consequences of co-exposure. Even worse, under some circumstances, traditional urinary biological exposure indices may also underestimate the risk (e.g. oCre with TOL/XYLs).
Considering all the data presented in this study (from exposures to mixtures and TOL alone), of all the biomarkers tested, MAs correlate best with Tol-A. In addition to being specific indicators, not endogenously produced, and sensitive to low atmospheric concentrations, MAs also appear to be less 
Table 1
Composition of the investigated mixtures Table 2 Descriptive statistics for biomarker concentrations with co-exposures. Tol-A was at 50 ppm -mean concentrations (± SD) 5.3 ± 0.6 3.8 ± 0.8 11.4 ± 2.3 1.9 ± 0.4 1.2 ± 0.3 6.7 ± 1.3 9.8 ± 1.9 8.0 ± 1.4 17.8 ± 3.1 5 5.6 ± 0.8 4.3 ± 0.9 10.6 ± 3.1 2.0 ± 0.4 1.3 ± 0.2 6.8 ± 1.2 10.1 ± 1.8 9.6 ± 2.1 19.7 ± 3.6 TOL50 EtAc40 0 < LOD 5.4 ± 1.6 < LOD < LOD < LOD < LOD / < LOD / 1 4.2 ± 0.7 4.4 ± 0.9 14.2 ± 4.3 2.0 ± 0.5 1.3 ± 0.3 6.9 ± 1.7 10.1 ± 2.4 7.9 ± 1.8 18.0 ± 3.8 5 3.6 ± 0.5 5.0 ± 0.8 15.2 ± 3.1 2.2 ± 0.4 1.4 ± 0.2 7.3 ± 1.2 10.9 ± 1.8 10.2 ± 3.2 21.1 ± 4.4 TOL50 EtAc400 0 < LOD 1.4 ± 0.8 < LOD < LOD < LOD < LOD / < LOD / 1 5.3 ± 1.9 3.1 ± 0.9 11.3 ± 3.8 1.8 ± 0.4 1.2 ± 0.3 6.2 ± 1.8 9.2 ± 2.5 8.5 ± 4.3 17.6 ± 6.8 5 5.3 ± 1.7 3.5 ± 1.1 10.8 ± 2.0 1.8 ± 0.2 1.1 ± 0.2 5.9 ± 1.2 8.8 ± 1.6 8.9 ± 3.4 17.7 ± 4.9
Co
TOL50 EtAc2000
0 < LOD 3.3 ± 1.3 < LOD < LOD < LOD < LOD / < LOD / 1 3.8 ± 1.2 4.6 ± 1.3 12.5 ± 6.1 1.7 ± 0.5 1.1 ± 0.4 6.4 ± 1.9 9.2 ± 2.7 8.3 ± 3.7 17.5 ± 6.2 5 3.7 ± 0.7 5.0 ± 1.8 12.8 ± 3.8 1.8 ± 0.3 1.2 ± 0.2 6.1 ± 1.1 9.0 ± 1.5 7.7 ± 3.1 16.7 ± 4.5
TOL50 BuOH2
0 < LOD 4.2 ± 0.9 < LOD < LOD < LOD < LOD / < LOD / 1 3.3 ± 0.9 4.3 ± 2.3 8.8 ± 3.0 1.5 ± 0.3 0.9 ± 0.2 5.1 ± 0.9 7.4 ± 1.4 7.4 ± 1.6 14.8 ± 2.5 5 3.0 ± 0.3 3.8 ± 0.7 7.9 ± 3.3 1.3 ± 0.4 0.7 ± 0.3 4.2 ± 1.5 6.2 ± 2.2 7.6 ± 3.3 13.7 ± 5.2
TOL50 BuOH20
0 < LOD 3.7 ± 0.5 < LOD < LOD < LOD < LOD / < LOD / 1 3.2 ± 0.3 4.2 ± 0.8 9.2 ± 2.3 1.4 ± 0.2 0.8 ± 0.1 4.7 ± 0.4 7.0 ± 0.7 7.3 ± 0.9 14.3 ± 1.5 5 3.2 ± 0.2 3.8 ± 0.7 9.0 ± 3.0 1.3 ± 0.2 0.8 ± 0.2 4.4 ± 0.9 6.5 ± 1.2 6.9 ± 1.8 13.4 ± 3.0 TOL50 BuOH100 0 < LOD 2.4 ± 0.6 < LOD < LOD < LOD < LOD / < LOD / 1 3.7 ± 0.5 4.8 ± 1.5 7.2 ± 2.8 1.4 ± 0.4 0.9 ± 0.3 4.4 ± 1.5 6.6 ± 2.2 5.8 ± 2.4 12.4 ± 4.4 5 4.3 ± 0.5 4.4 ± 0.9 5.5 ± 1.7 1.2 ± 0.3 0.7 ± 0.3 3.9 ± 1.2 5.8 ± 1.8 5.0 ± 2.0 10.8 ± 3.8
TOL50 MEK20
0 < LOD 2.2 ± 2.1 < LOD < LOD < LOD < LOD / < LOD / 1 8.9 ± 1.4 5.9 ± 2.2 23.2 ± 6.7 4.1 ± 0.8 2.9 ± 0.6 13.7 ± 2.9 20.6 ± 4.1 24.2 ± 5.6 44.8 ± 8.4 5 6.5 ± 1.6 4.9 ± 1.7 18.2 ± 8.0 3.1 ± 0.7 2.3 ± 0.6 9.9 ± 2.5 15.2 ±3.7 21.0 ± 15.1 36.2 ± 18.5 TOL50 MEK200 0 < LOD 6.8 ± 1.5 < LOD < LOD < LOD < LOD / < LOD / 1 22.8 ± 2.3 7.2 ± 0.8 30.0 ± 5.7 2.6 ± 0.3 1.3 ± 0.2 5.9 ± 1.7 9.7 ± 1.9 15.9 ± 5.5 25.6 ± 6.9 5 17.7 ± 3.5 4.6 ± 0.9 29.1 ± 5.1 2.7 ± 0.2 1.4 ± 0.3 6.9 ± 1.3 11.0 ± 1.8 16.9 ± 3.3 27.9 ± 4.9 TOL50 MEK1400 0 < LOD 2.8 ± 0.7 < LOD < LOD < LOD < LOD / < LOD / 1 25.4 ± 3.3 4.2 ± 0.9 23.1 ± 4.6 1.7 ± 0.3 0.5 ± 0.1 2.3 ± 0.5 4.5 ± 0.8 7.2 ± 1.4 11.7 ± 1.8 5 22.1 ± 3.9 5.7 ± 0.9 24.0 ± 3.7 2.2 ± 0.2 1.0 ± 0.2 5.1 ± 0.9 8.3 ± 1.3 12.3 ± 2.4 20.7 ± 3.1
TOL50 XYLs5
0 < LOD 3.2 ± 1.5 < LOD < LOD < LOD < LOD / < LOD / 1 5.4 ± 1.0 3.2 ± 0.6 11.3 ± 2.2 2.0 ± 0.3 1.3 ± 0.2 6.4 ± 1.6 9.8 ± 2.2 9.8 ± 4.6 19.6 ± 6.5 5 4.7 ± 0.7 4.0 ± 0.6 10.6 ± 3.1 1.7 ± 0.6 1.1 ± 0.4 5.6 ± 2.3 8.4 ± 3.2 8.7 ± 5.4 17.1 ± 8.3
TOL50 XYLs50
0 < LOD 4.3 ± 1.3 < LOD < LOD < LOD < LOD / < LOD / 1 9.5 ± 5.2 3.7 ± 0.7 9.1 ± 2.9 1.7 ± 0.4 1.1 ± 0.3 5.5 ± 1.5 8.2 ± 2.1 8.2 ± 3.1 16.4 ± 5.0 5 9.3 ± 2.2 3.8 ± 0.9 11.9 ± 4.4 1.9 ± 0.6 1.2 ± 0.4 6.4 ± 2.5 9.5 ± 3.5 9.7 ± 3.8 19.2 ± 7.0 TOL50 XYLs400
18.2 ± 1.7 3.9 ± 0.6 7.7 ± 1.0 1.5 ± 0.4 0.8 ± 0.2 5.0 ± 1.5 7.3 ± 2.1 7.5 ± 3.3 14.8 ± 4.9 5
18.4 ± 1.3 3.0 ± 0.6 8.2 ± 0.6 1.6 ± 0.4 0.8 ± 0.2 4.8 ± 1.2 7.2 ± 1.8 8.5 ± 3.8 15.6 ± 5.4 a Days 0 corresponds to the control measurement carried out 3 days before the beginning of the inhalation exposure b n = 8 except for TOL50XYLs400 (= 7 on day 5) Table 3 Descriptive statistics for biomarker concentrations with co-exposures. Tol-A was equal to 5 or 500 ppm. and co-solvent concentrations were maintained at their OEL -mean concentrations (± SD) 
TOL500
MEK200
0 < LOD 3.5 ± 0.9 < LOD < LOD < LOD < LOD / < LOD / 1 252 ± 38 14.2 ± 1.7 117 ± 15 13 ± 2 6.0 ± 1.0 35 ± 6 54 ± 8 81 ± 22 135 ± 25 5 217 ± 54 19.5 ± 2.6 129 ± 18 17 ± 3 7.5 ± 1.3 43 ± 7 68 ± 11 108 ± 43 176 ± 50 TOL500 XYLs50 0 < LOD 5.4 ± 1.6 < LOD < LOD < LOD < LOD / < LOD / 1 262 ± 50 27.6 ± 4.2 101 ± 15 16 ± 2 8.1 ± 1.2 49 ± 8 73 ± 9 134 ± 65 207 ± 74 5 208 ± 37 14.2 ± 2.3 104 ± 18 18 ± 4 8.7 ± 1.9 51 ± 10 77 ± 15 143 ± 79 219 ± 92 a Days 0 corresponds to the control measurement carried out 3 days before the beginning of the inhalation exposure b n = 8 except for TOL5/BuOH20 (= 7 on day 1 and = 6 on day 5) and TOL500/BuOH20 (= 7 on day 5) Table 5 Correlation coefficients for the log-log relationship between each indicator and Tol-A when considering full range of Tol-A (0 -500 ppm) or reduced Tol-A (≤ 50 ppm) Figure 3 . Dose -response relationships for mixtures (co-solvents at their 8h-OEL) (A) Tol-B for TOL+EtAc400 and TOL+ MEK200; (B) Tol-B for TOL+BuOH20 and TOL+XYLs50; (C) HA for TOL+EtAc400 and TOL+ MEK200; (D) HA for TOL+BuOH20 and TOL+XYLs50; (E) oCre for TOL+EtAc400 and TOL+ MEK200; (F) oCre for TOL+BuOH20 and TOL+XYLs50; (G) ∑MAs for TOL+EtAc400 and TOL+ MEK200; (H) ∑MAs for TOL+BuOH20 and TOL+XYLs50.
